呋喹替尼用于经两线化疗后晚期非鳞非小细胞肺癌的随机双盲安慰剂对照多中心II期研究
主要终点为盲法独立中心评审(BICR)的無进展生存期(PFS),呋喹替尼组中位PFS为3.8个月(HR 0.34,95%CI 0.20-0.57,P<.001),客观缓解率和疾病控制率均显著优于安慰剂,安全性可接受。
要点
- 呋喹替尼三线或四线治疗晚期非鳞NSCLC,BICR评估中位PFS为3.8个月,HR 0.34(95%CI 0.20-0.57,P<.001)。
- 客观缓解率13.1% vs 0%,疾病控制率60.7% vs 13.3%(P=.041和<.001)。
- ≥3级治疗中出现的不良事件常见高血压(8.2%)、手足综合征(4.9%)和蛋白尿(4.9%)。
核心结论
- 对于经两线化疗后进展的晚期非鳞NSCLC,呋喹替尼三线或四线治疗优于安慰剂,且安全性可接受。
研究设计与样本
- 呋喹替尼口服5 mg每日一次,4周为一周期,用药3周停1周;主要终点为BICR评估的PFS。
主要发现
- BICR和研究者评估的中位PFS均为3.8个月(BICR HR 0.34,95%CI 0.20-0.57,P<.001)。
- 呋喹替尼组3个月和6个月生存率分别为90.2%和67.2%,安慰剂组分别为73.3%和58.8%。
- 客观缓解率呋喹替尼组13.1% vs 安慰剂组0%(P=.041),疾病控制率60.7% vs 13.3%(P<.001)。
- ≥3级治疗中出现的不良事件:高血压8.2%、手足综合征4.9%、蛋白尿4.9%。
临床怎么用
- 对于经两线化疗后进展的晚期非鳞NSCLC患者,可考虑使用呋喹替尼5 mg每日一次(用3周停1周)作为三线或四线治疗选择。
- 治疗期间需监测高血压、手足综合征和蛋白尿等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Patients with advanced non‒small-cell lung cancer (NSCLC) who fail two lines of chemotherapy have unmet medical needs. The kinase inhibitor fruquintinib selectively targets vascular endothelial growth factor receptors and, hence, tumor angiogenesis and lymphogenesis. This randomized, double-blind, placebo-controlled, multicenter phase II trial evaluated the efficacy and safety of fruquintinib in patients with advanced nonsquamous NSCLC who experienced disease progression after second-line chemotherapy. Patients and Methods Eligible patients were randomly assigned (two to one; stratified by epidermal growth factor receptor status) to receive fruquintinib or placebo, both in combination with best supportive care. Oral fruquintinib (5 mg once daily) was given in 4-week cycles of 3 weeks of treatment followed by 1 week off. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1. The primary end point was progression-free survival (PFS) evaluated by a blinded image central review (BICR) committee. Secondary end points included investigator-evaluated PFS, objective response rate, disease control rate, overall survival, and safety. Results Ninety-one patients from 12 hospitals received treatment with fruquintinib (n = 61) or placebo (n = 30). Median PFS was 3.8 months with fruquintinib by both BICR and investigators' evaluations (hazard ratio by BICR, 0.34; 95% CI, 0.20 to 0.57; P < .001). Three- and 6-month survival rates were 90.2% and 67.2% in the fruquintinib group and 73.3% and 58.8% in the placebo group, respectively. The objective response rate and disease control rate were 13.1% and 60.7% with fruquintinib, compared with 0% and 13.3% with placebo ( P = .041 and < .001), respectively. The most common treatment-emergent adverse events with fruquintinib (≥ grade 3) were hypertension (8.2%), hand-foot syndrome (4.9%), and proteinuria (4.9%). Conclusion Third- and fourth-line fruquintinib for advanced NSCLC was superior to placebo and had an acceptable safety profile.
引用
- Lu S, Chang J, Liu X, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 29528793. doi:10.1200/JCO.2017.76.7145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。